REG - Hemogenyx Pharma Plc - Placing to Raise £534,375

Hemogenyx PharmaceuticalsAnnouncement

28/11/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231128:nRSb9397Ua&default-theme=true

RNS Number : 9397U  Hemogenyx Pharmaceuticals PLC  28 November 2023

28 November 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON
LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE,
PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT. THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU)
NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS WERE
TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE
RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO
BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN
POSSESSION OF INSIDE INFORMATION.

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Placing to Raise £534,375

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group
developing new therapies and treatments for blood diseases, is pleased to
announce that it has successfully raised £534,375 (before expenses) through
the allotment and issue of 22,500,000 new ordinary shares at 2.375 pence per
share (the "Placing", "Placing Shares"). The Placing was oversubscribed and
conducted on behalf of the Company by its corporate broker, Peterhouse Capital
Limited.

 

The net proceeds from the Placing will be used to facilitate progression of
the Company's Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") for the
treatment of acute myeloid leukaemia ("AML"). Specifically, and as outlined by
the Company in its announcement of 15 November 2023, this fundraise will help
the Company to accelerate the completion of work set out in the plan presented
and agreed to by the FDA and to re-submit the Investigational New Drug ("IND")
application for the HEMO-CAR-T product. The funds will also enable the
Company, in view of recently announced successes, to provide modest additional
resources to the development of its CBR platform.

 

An application is being made to the London Stock Exchange Main Market and
admission of the Placing Shares to trading is expected on or around 4 December
2023 ("Admission"). The Placing Shares will rank pari passu with the
existing ordinary shares in the Company.

 

Total Voting Rights

 

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
1,175,565,988 ordinary shares. The Company does not hold any shares in
treasury. The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.

 

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

 

"The markets have at last started to recognise the significant recent progress
that the Company has made in the development of both HEMO-CAR-T and CBR
platform. Today's Placing will enable the Company to progress with its
ambitious schedule to move forward to clinical trials of this exciting
potential treatment for AML as well as to further expand the use our CBR
platform for the treatment of solid tumours."

 

For the purposes of UK MAR, the person responsible for arranging for the
release of this Announcement on behalf of the Company is Dr Vladislav Sandler,
Chief Executive Officer & Co-Founder.

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

 

The Company is a pre-clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses as engines
for novel product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOELVLFLXFLFFBQ